Analysts remain divided on Gogo Inc.'s trajectory as the in-flight connectivity provider navigates its 5G network launch against a backdrop of strategic shifts and evolving satellite technology debates.
Investment firm Maxim Group reaffirms its Buy rating and $1.50 price target for Strive Inc., following the company's transformative acquisition of Semler Scientific, which positions it as a major corporate Bitcoin holder and expands its healthcare tech footprint.
Reed Jobs, son of the late Apple co-founder Steve Jobs, has secured over $200 million for Yosemite, a venture fund dedicated to pioneering cancer treatments. Backed by major institutions, the fund seeks to transform cancer from a fatal diagnosis to a chronic, manageable disease within a generation.
Once a fintech stalwart, Fiserv shares have cratered 70% in a year. As its 'One Fiserv' restructuring plan kicks in, investors are grappling with whether the beaten-down stock is a bargain or a warning sign.
A recent report by Congressional Democrats highlights rising costs for Arizonans, but a local economist argues the figures lack crucial context on 'normal' inflation, igniting a political firestorm over economic messaging.
Standex International reports robust second-quarter results, with organic growth reaching 6.4% and record quarterly orders. The company's strategic pivot towards high-growth markets like electrical grid infrastructure and new product development is now materially boosting the top line.
President Trump's surprise nomination of former Fed Governor Kevin Warsh to lead the central bank sends mixed signals to investors, stirring debate over future monetary policy and market stability.
Cocoa prices staged a modest technical rebound on Friday, halting a month-long slide that had pushed contracts to their lowest levels in over two years. The move higher, driven by short-covering in an oversold market, comes amid a complex backdrop of abundant near-term supplies, weakening demand, and a tightening longer-term outlook.
While Urban Outfitters shares have underperformed the broader market, diving 8.2% over six months, a deeper look reveals a complex picture of robust profitability growth tempered by slowing revenue expansion, leaving investors to weigh its potential against evident risks.
Polish cybersecurity authorities have attributed a wave of disruptive cyberattacks in late December to a hacking group linked to Russia's FSB, marking a potential escalation in tactics against energy and heating infrastructure during a severe winter storm.
The Cleveland-based RIA platform has appointed three senior executives as its assets under management soar, positioning the firm for its ambitious target of $20 billion by 2027.
The U.S. rig count saw a marginal increase this week, yet remains significantly below last year's levels as crude production dips and completions activity sends conflicting signals.
Three decades on, Warren Buffett's 1994 shareholder letter, featuring his iconic 'Hope Diamond' analogy, continues to offer a masterclass in capital allocation, challenging the modern obsession with control and highlighting the power of partial ownership in exceptional businesses.
Advocate Health, the nation's third-largest nonprofit health system, is investing over $800 million in enhanced compensation and benefits for its 165,000+ employees, raising its minimum wage and expanding tuition aid, mental health support, and paid volunteer time.
Thermo Fisher Scientific posted stronger-than-expected Q4 revenue and profit, driven by new products and strategic deals. However, the stock fell as investors weighed pressures in key academic and government markets against the company's solid 2026 outlook.
Analyst sell ratings are rare on Wall Street, making them noteworthy when they appear. We examine one such case where pessimism may have gone too far, creating a potential opportunity, alongside two stocks where the cautious outlook appears justified.
While small-cap stocks can offer unique growth opportunities away from Wall Street's spotlight, their inherent risks demand careful scrutiny. We examine three companies where valuation concerns and competitive pressures suggest caution may be warranted.
Analysts have pinned high hopes on several names, but a closer look reveals a more nuanced picture. We examine one company likely to justify the optimism and two where significant risks may be overshadowing the bullish price targets.
While the allure of finding the next undervalued gem is strong, some stocks trading at low multiples may be cheap for a reason. We examine three companies where fundamental challenges could outweigh their seemingly attractive valuations.
KeyBanc Capital Markets has upgraded LivaNova PLC (LIVN) from Sector Weight to Overweight, setting an $81 price target. The move reflects a broader positive shift in analyst sentiment towards the medical technology sector as valuation premiums ease.
